European regulators say there's 'no indication' the AstraZeneca COVID-19 vaccine is linked to blood clots, after some countries temporarily suspended the vaccine's use.
Danish authorities said they were suspending their use of the jab, after reports that a vaccinated person in the country died from a blood clot.
The Danish health minister Magnus Heunicke said it was too early to say whether there was a link between the vaccine and the blood clot, but that they were 'acting early' while the issue was investigated.
The Danish Health Authority said it will act "swiftly and promptly if there is the slightest indication of possible risks associated with the vaccine".
Use of the vaccine in Denmark is being paused for 14 days, and the decision will then be reviewed.
Norway and Iceland have also temporarily halted their use of the AstraZeneca vaccine as a precaution over the concerns around blood clot reports.
Several other countries - including Italy, Austria, Luxembourg, Estonia and Latvia - have stopped using particular batches of the vaccine.
The European Medicines Agency (EMA) is investigating the issue.
In a statement, the EMA said: "There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine.
"The position of EMA’s safety committee PRAC is that the vaccine’s benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing."
It adds the the number blood clot events in vaccinated people is 'no higher' than in the general population.
In total, 30 such cases have been reported among nearly five million people vaccinated with the AstraZeneca vaccine in the EEA.
Meanwhile, the National Immunisation Advisory Group has recommended the use of the AstraZeneca vaccine for over 70s here.
They'd previously said older people should receive the Pfizer and Moderna vaccines wherever possible.
The AstraZeneca vaccine is one of three vaccines being used here.
A fourth - from Johnson & Johnson - is set to be used shortly after the EU yesterday gave it the green light.
